For citations:

Lee C.H., Wan Y., Smith A., Xie R., Motzer R.J. Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma. Cancer Urology. 2021;17(4):54-64. (In Russ.) https://doi.org/10.17650/1726-9776-2021-17-4-54-64